With the purchase of Organon & Co., billionaire Dilip Shanghvi's Sun Pharmaceutical Industries' annual revenue will more than ...

Big, contrarian acquisitions are not new territory for Shanghvi. He took bold calls with Taro Pharmaceuticals in 2010 and ...

Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based ...

And yet, the man who authored this audacious move—executive chairman Dilip Shanghvi, now 70—said what he always says when the ...

The Indian pharma tycoon has made 17 acquisitions before this, but this is the first time he's borrowing money for a buyout.

Sun Pharma's $11.75 billion buyout of Organon signifies a strategic shift from focusing on the US generics market to seeking ...

Sun Pharma’s $11.75 billion all-cash acquisition of Organon marks its biggest overseas deal yet, propelling Dilip Shanghvi’s ...

Sun Pharma Executive Chairman Dilip Shanghvi said that it is not a very high debt ratio, even though the amount of debt would ...

Sun Pharmaceutical Industries' acquisition of US-based Organon & Co at USD 11.75 billion enterprise valuation is both a ...

Sun Pharma Chairman Dilip Shanghvi described the Organon acquisition as both exciting and worrying due to its size and debt ...

The deal, expected to close in early next year, will help Sun Pharma leapfrog into the Top 25 global pharmaceutical companies ...

Sun Pharmaceutical Industries' acquisition of US-based Organon & Co at USD 11.75 billion enterprise valuation is both a "happy" and "bit anxious" moment, considering the large nature of the ...